A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
about
Biochemical markers in preclinical models of osteoporosis.Effects of rabeprazole on bone metabolic disorders in a gastrectomized rat modelTargeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.Autophagic flux inhibition and lysosomogenesis ensuing cellular capture and retention of the cationic drug quinacrine in murine models.A proteomic study of protein variation between osteopenic and age-matched control bone tissue.Comparative analysis of the effects of a novel vacuolar adenosine 5'-triphosphatase inhibitor, FR202126, and doxycycline on bone loss caused by experimental periodontitis in rats
P2860
A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A vacuolar ATPase inhibitor, F ...... tial for clinical application.
@en
A vacuolar ATPase inhibitor, F ...... tial for clinical application.
@nl
type
label
A vacuolar ATPase inhibitor, F ...... tial for clinical application.
@en
A vacuolar ATPase inhibitor, F ...... tial for clinical application.
@nl
prefLabel
A vacuolar ATPase inhibitor, F ...... tial for clinical application.
@en
A vacuolar ATPase inhibitor, F ...... tial for clinical application.
@nl
P356
P1476
A vacuolar ATPase inhibitor, F ...... ntial for clinical application
@en
P2093
Mikiko Takano
Nobuaki Takeshita
P2860
P304
P356
10.1359/JBMR.050517
P577
2005-05-31T00:00:00Z